Many seniors surveyed felt they knew small or nothing at all about the Medicare medication discount cards. Additionally, just 20 % of these surveyed were alert to the Medicare credit of $600 designed for low-income Medicare beneficiaries to greatly help them pay for prescription medications. When they find out about the Medicare credit, a lot more than four out of five believe it will be beneficial to low-income Medicare beneficiaries, including two-thirds who believe it shall be very helpful. Related StoriesMembers enrolled in Medicare Advantage satisfied with their plans, research findsGenomic Wellness announces Medicare coverage for Oncotype DX prostate cancer tumor testTissue Regenix strengthens position in post-acute wound treatment market with Medicare insurance for Dermapure’The Pharmacy Treatment Alliance survey demonstrates Medicare beneficiaries who need the most help with their prescription medication costs are eager to learn even more and wanting to receive the assistance the Medicare drug discount cards provides,’ said Mary Ann Wagner, customer and president wellness advisor for the Pharmacy Care Alliance.No significant increase in the rate of serious hypoglycemia was seen among sufferers in the sitagliptin group, in comparison with the placebo group. Fewer sufferers in the sitagliptin group required the usage of additional antihyperglycemic agents or initiated long-term insulin therapy during the study period. Concern offers been raised about a possible association between incretin-based therapies and adverse pancreatic results.15 Although acute pancreatitis was uncommon, it occurred more often in the sitagliptin group, but the difference had not been significant. Pancreatic cancers was also uncommon and occurred more often in the placebo group, but once again the difference had not been significant. The observation that sitagliptin therapy was not associated with a change in long-term rates of cardiovascular events is in keeping with the findings from shorter-term outcome trials of additional DPP-4 inhibitors, including alogliptin and saxagliptin.9,10 However, results from the SAVOR-TIMI 53 trial showed an unexpected excess rate of hospitalization for heart failure in the saxagliptin group .8 The EXAMINE trial showed a non-significant numerical imbalance in hospitalization for heart failure in the alogliptin group in comparison with placebo but no imbalance in a post hoc evaluation of the composite of hospitalization for heart failure or cardiovascular loss of life.16 In contrast, in our trial we discovered that prices of hospitalization for heart failure did not differ between the two groups.